Anixa Biosciences (ANIX) Accounts Payables (2010 - 2026)
Anixa Biosciences' (ANIX) quarterly Accounts Payables came in at $252000.0 in Q2 2026, down 11.27% YoY from $284000.0 in Q2 2025, and up 52.73% on a QoQ basis from $165000.0 in Q4 2025.
Anixa Biosciences (ANIX) Accounts Payables (2010 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 17 years of Accounts Payables data on file, last reported at $252000.0 in Q2 2026.
- Quarterly Accounts Payables fell 11.27% year-over-year to $252000.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $252000.0 (down 11.27% YoY) and the FY2025 annual result came in at $165000.0, down 68.57% from the prior year.
- Accounts Payables improved to $252000.0 in Q2 2026, from $165000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $600000.0 in Q1 2025 to a low of $93000.0 in Q2 2022.
- A 5-year average of $275117.6 and a median of $252000.0 in 2026 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables slumped 78.77% — and 2024, when it soared 230.91%.
- Tracing ANIX's Accounts Payables over 5 years: stood at $265000.0 in 2022, then fell by 22.26% to $206000.0 in 2023, then soared by 154.85% to $525000.0 in 2024, then sank by 68.57% to $165000.0 in 2025, then surged by 52.73% to $252000.0 in 2026.
- The last three Accounts Payables figures came in at $252000.0 (Q2 2026), $165000.0 (Q4 2025), and $276000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 35.57 Mn |
| 10 | Anixa Biosciences | 125.30 Mn | 125.30 Mn | - | 252,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 252,000.00 |
| Oct 31, 2025 | 165,000.00 |
| Jul 31, 2025 | 276,000.00 |
| Apr 30, 2025 | 284,000.00 |
| Jan 31, 2025 | 600,000.00 |
| Oct 31, 2024 | 525,000.00 |
| Jul 31, 2024 | 302,000.00 |
| Apr 30, 2024 | 215,000.00 |
| Jan 31, 2024 | 364,000.00 |
| Oct 31, 2023 | 206,000.00 |
| Jul 31, 2023 | 94,000.00 |
| Apr 30, 2023 | 195,000.00 |
| Jan 31, 2023 | 110,000.00 |
| Oct 31, 2022 | 265,000.00 |
| Jul 31, 2022 | 227,000.00 |
| Apr 30, 2022 | 93,000.00 |
| Jan 31, 2022 | 504,000.00 |
| Oct 31, 2021 | 136,000.00 |
| Jul 31, 2021 | 207,733.00 |
| Apr 30, 2021 | 438,013.00 |